Navigation Links
SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
Date:9/16/2008

TSX symbol: SBS

CALGARY, Sept. 16 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it is eligible to proceed with its planned Phase I/II human clinical trial of plant-produced insulin now that the 30-day review period of its Investigational New Drug (IND) application has passed. SemBioSys submitted the application in July to the U.S. Food and Drug Administration (FDA), which has now completed its review of the file. As previously announced, SemBioSys intends to conduct the Phase I/II insulin trial in Europe. Prior to proceeding with the planned trial in the United Kingdom, the company's Clinical Trial Application (CTA) must be reviewed by the appropriate European regulatory authorities.

"The company continues to achieve its insulin development milestones on time. Our recent accomplishments confirm our confidence in our regulatory and development strategy using plants as a low-cost production host for insulin. Plant-produced human recombinant insulin represents a major step forward in insulin production. We believe, furthermore, that these upcoming studies could prove to be the greatest achievement in insulin production since the advent of recombinant human insulin in the early 80's," said Andrew Baum, president and chief executive officer of SemBioSys. "The purpose of filing an IND in the U.S., even though we intend to conduct the trial in Europe, is to ensure that we can pursue U.S. and European regulatory approval of our plant-produced insulin contemporaneously. Conducting the planned insulin trial in Europe allows us to establish the bioequivalence of our safflower-produced insulin to commercially available insulin products from both the U.S. and Europe in a single trial."

SemBioSys plans to initiate a Phase I/II human trial of its safflower-produced insulin in the United Kingdom during the f
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 04, 2015 Genedata, a leading ... and life science research, today announced the release ... version of its enterprise solution for biologics R&D. ... more efficient discovery and development of novel biotherapeutics. ... and address protein optimization and developability requirements. Genedata ...
(Date:5/4/2015)... 4, 2015   Tocagen Inc. , a ... from Tocagen,s ongoing investigational studies were presented at ... American Association of Neurological Surgeons (AANS)/Congress of Neurological ... 2015, in Washington, D.C. ... meeting with FDA and continues to advance towards ...
(Date:5/1/2015)... May 01, 2015 OncoTAb, Inc., ... Charlotte) spin-out company, announced that Pinku Mukherjee, Ph.D. has ... UNC Board of Governors’ highest faculty honor. Mukherjee received ... welfare , for her innovative research and development of ... Award represents a crowning moment in my scientific career,” ...
(Date:5/1/2015)... LONDON , May 1, 2015 ... following equities: Genetic Technologies Ltd (NASDAQ: GENE ... Thermo Fisher Scientific Inc. (NYSE: TMO ), ... Inc. (NYSE: PKI ). Free research report ... http://get.Investor-Edge.com/pdf/?c=Genetic%20Technologies&d=01-May-2015&s=GENE . On Thursday, April 30, 2015, the ...
Breaking Biology Technology:Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5
... for preclinical and clinical research projects in Parkinson,s disease-related ... ... 14 The Michael J. Fox Foundation,for Parkinson,s Research (MJFF) ... speed development of effective therapies for the,under-addressed cognitive and mood-related ...
... China, Oct. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... (NASDAQ: CSKI ), a,leading fully integrated pharmaceutical ... China ("PRC"), announced today that it,started production at ... company that it acquired, on October 14, 2008., ...
... discuss positive corporate developments and update,investors on ... SANTA CLARA, Calif., Oct. 14 NewCardio, ... and services company, today,announced that management will ... developments and provide an update on the ...
Cached Biology Technology:Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 2Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 3Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 4Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinson's Disease 5China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 2China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance 3NewCardio Management to Host Conference Call on October 21 2NewCardio Management to Host Conference Call on October 21 3
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... The global warming debate has focused on carbon dioxide ... a lesser-known mechanism -- dirty snow -- can explain ... to greenhouse gases. , Snow becomes dirty when soot ... atmosphere and falls to the ground. Soot-infused snow is ...
... NIH/NRSA postdoctoral fellow at the University of Oregon, has shown ... recruit soil bacteria needed to provide a natural fertilizer to ... to boost crop yields may instead be contributing to growth ... to years of research both in the test tube and, ...
... – Cold Spring Harbor Laboratory (CSHL) researchers led by ... Medical Investigator (HHMI) Greg Hannon have identified a family ... suppressor network, called the p53 pathway, to fight cancer ... several fronts to understand the p53 pathway because damage ...
Cached Biology News:Dirty snow may warm Arctic as much as greenhouse gases 2Pesticides choke pathway for nature to produce nitrogen for crops 2Pesticides choke pathway for nature to produce nitrogen for crops 3Study shows big power of small RNAs, not just proteins, in halting cancer 2
Mouse polyclonal antibody to QPRT - quinolinate phosphoribosyltransferase (nicotinate-nucleotide pyrophosphorylase (carboxylating))...
... Optimization Kits without ammonium sulfate are compatible ... such as Taq and AmpliThem™™ DNA polymerases. ... PCR systems in one experiment by adding ... into the PreMixes supplied with the kit. ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... A cleaning agent for removing ... countertops, and pipettors. It ... RNase contamination from microcentrifuge tubes ... ,RNase Zap (R) ...
Biology Products: